Stockscreener 앱 받기
128.38
0.49%
0.62
시간 외 거래:
128.38
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza - Yahoo Finance UK
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Eagle Health Investments LP - MarketBeat
JPMorgan Chase & Co. Has $664.02 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $176.00 at JPMorgan Chase & Co. - MarketBeat
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $140.00 by Analysts at Truist Financial - MarketBeat
Truist cuts Neurocrine Bio stock price target on higher spending By Investing.com - Investing.com Canada
M&G PLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the GARP Strategy with Strong Growth and Reasonable Valuation - ChartMill
Wall Street Zen Downgrades Neurocrine Biosciences (NASDAQ:NBIX) to Buy - MarketBeat
Volatility Watch: Is Appian Corporations ROIC above industry averageMarket Activity Report & Technical Buy Zone Confirmation - baoquankhu1.vn
Neurocrine Biosciences (NBIX) Valuation Check After Strong 2025 Results And Late Stage Pipeline Progress - simplywall.st
Why Neurocrine Biosciences Inc. (NB3) stock is a strong analyst pickQuarterly Growth Report & Safe Entry Zone Identification - mfd.ru
Technical Reactions to NBIX Trends in Macro Strategies - Stock Traders Daily
Market Rankings: Why is Neurocrine Biosciences Inc. stock going upWeekly Trend Report & Technical Pattern Based Signals - mfd.ru
Can Neurocrine Biosciences Inc. maintain its current growth rateStop Loss & AI Powered Buy and Sell Recommendations - mfd.ru
Neurocrine Biosciences (NBIX) Is Down 12.1% After Issuing 2026 INGREZZA Sales GuidanceWhat's Changed - simplywall.st
Why Neurocrine Biosciences Inc. stock remains a top recommendationJuly 2025 Fed Impact & Long-Term Safe Investment Plans - mfd.ru
A Look At Neurocrine Biosciences (NBIX) Valuation After Strong 2025 Results And 2026 Guidance - Yahoo Finance
How cyclical is Neurocrine Biosciences Inc.’s revenue streamWeekly Investment Recap & Low Risk Profit Maximizing Plans - mfd.ru
NBIX Rating Maintained, Price Target Lowered by Wells Fargo | NB - GuruFocus
Wells Fargo & Company Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Krilogy Financial LLC Makes New $1.27 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment - ChartMill
Neurocrine Biosciences Enters New Growth Phase With Broader Revenue Mix - simplywall.st
Neurocrine Biosciences: Growth Beyond Just Ingrezza (NASDAQ:NBIX) - Seeking Alpha
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor - BioPharma Dive
Neurocrine Biosciences (NASDAQ:NBIX) Given New $204.00 Price Target at Citigroup - MarketBeat
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance - Benzinga
Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting (NASDAQ:NBIX) - Seeking Alpha
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at Royal Bank Of Canada - MarketBeat
BMO Capital Markets Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says - marketscreener.com
Wedbush Adjusts Neurocrine Biosciences Price Target to $151 From $149, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $151.00 at Wedbush - MarketBeat
Neurocrine Bio. stock price target lowered to $192 at H.C. Wainwright - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 9.3% Following Analyst Downgrade - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Given New $192.00 Price Target at HC Wainwright - MarketBeat
Needham & Company LLC Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $185.00 - MarketBeat
RBC Trims Price Target on Neurocrine Biosciences to $177 From $180, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript - Insider Monkey
Forecasting The Future: 10 Analyst Projections For Neurocrine Biosciences - Benzinga
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Impax Asset Management Group plc - MarketBeat
Is Neurocrine Biosciences (NBIX) Pricing Reflecting Its Strong 1 Year Share Performance? - simplywall.st
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Ins - GuruFocus
Neurocrine Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Neurocrine Biosciences (NASDAQ:NBIX) Posts Earnings Results, Misses Estimates By $0.48 EPS - MarketBeat
Neurocrine Biosciences Q4 Earnings Call Highlights - MarketBeat
Neurocrine Q4 2025 slides: INGREZZA, CRENESSITY fuel 22% annual growth - Investing.com India
Earnings call transcript: Neurocrine’s Q4 2025 beats forecasts, stock rises By Investing.com - Investing.com India
Earnings call transcript: Neurocrine’s Q4 2025 beats forecasts, stock rises - Investing.com
Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates - Yahoo Finance
Neurocrine: Q4 Earnings Snapshot - KVUE
Neurocrine: Fourth Quarter Earnings Overview - Bitget
Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance - Investing.com Australia
Neurocrine Biosciences Fiscal Q4 Adjusted Earnings, Revenue Rise; Sets INGREZZA FY Guidance - marketscreener.com
Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance By Investing.com - Investing.com South Africa
Neurocrine Biosciences Inc Profit Advances In Q4 - Nasdaq
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M - marketscreener.com
Neurocrine Biosciences (NASDAQ: NBIX) posts 2025 INGREZZA surge and details DOJ probe - Stock Titan
0.32%
0.14%
자본화:
|
볼륨(24시간):